What is QUADRAMET®?
QUADRAMET® is an injectable radiopharmaceutical used to treat bone pain associated with certain kinds of cancer in men and women.
It is primarily used to treat the pain associated with osteoblastic and mixed bone metastases confirmed on a radionuclide bone scan and has demonstrated efficacy in patients with prostate, breast and other primary cancers.1-3
◆ Rapid and lasting pain relief1,2,4,5
◆ Single-dose therapy, which minimizes treatment burden1
◆ An established safety profile for treatment confidence1,6
Patient resource for healthcare professionals:
QUADRAMET® Question and Answer Guide for Patients
A patient guide to understanding QUADRAMET®
Please see Indications, Important Safety Information and Prescribing Information below.
Please contact us if you have any questions
Adverse events or
product quality complaints
Use appropriate country code if outside US
References: 1. QUADRAMET® [package insert]. N. Billerica, MA: Lantheus Medical Imaging, Inc.; 2014. 2. Sartor O, Reid RH, Hoskin PJ, et al. Samarium-153-lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology. 2004;63(5):940-945. 3. Morris M. et al., Phase I Study of Samarium-153 Lexidronam With docetaxel in Castration-Resistant Metastatic Prostate Cancer, Journal of Clinical Oncology, 2009;27:2436-2442. 4. Serafini AN, Houston SJ, Resche I, et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol. 1998;16(4):1574-1581. 5. Baczyk M, Czepczynski R, et al. 89-Sr versus 153-Sm- EDTMP: comparison of treatment efficacy of painful bone metastases in prostate and breast carcinoma. Nuc Med Commun. 2007;28(4):245-250. 6. Data on file, Lantheus Medical Imaging, Inc.
QUADRAMET® is indicated for relief of pain in patients with confirmed osteoblastic metastatic bone lesions that enhance on radionuclide bone scan.
SELECTED IMPORTANT RISK INFORMATION ABOUT QUADRAMET®
CONTRAINDICATIONS: QUADRAMET® is contraindicated in patients who have known hypersensitivity to EDTMP or similar phosphonate compounds.
WARNINGS and PRECAUTIONS: QUADRAMET® causes bone marrow suppression. Before administered, the patient's current clinical, hematological status, and bone marrow response history to myelotoxic agents should be considered. Metastatic prostate and other cancers can be associated with disseminated intravascular coagulation (DIC); caution should be exercised in treating cancer patients whose platelet counts are falling or who have other findings suggesting DIC. Blood counts should be monitored weekly for at least 8 weeks or until bone marrow recovery.
The potential for additive bone marrow toxicity of QUADRAMET® with chemotherapy or external beam radiation has not been studied. QUADRAMET® should not be administered concurrently with either of these treatments unless the benefits outweigh the risks. QUADRAMET® should not be given after either of these treatments until there has been time for adequate marrow recovery.
QUADRAMET® can cause fetal harm. Women of childbearing potential should be advised to avoid becoming pregnant soon after receiving QUADRAMET®. If administered, pregnant patients should be apprised of the potential hazard to the fetus and the potential for serious adverse reactions in nursing infants.
ADVERSE EVENTS: The most frequent events are thrombocytopenia, leukopenia, and decreased hemoglobin.
This site is intended for U.S. Healthcare Professionals only.
QUADRAMET and Lantheus logo display are registered trademarks of Lantheus Medical Imaging, Inc.
©2020 Lantheus Medical Imaging, Inc. All Rights Reserved.